electroCore, Inc.（ECOR）财务数据ECORelectroCore, Inc.

electroCore, Inc. (ECOR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is United States Rx, accounting for 77.4% of total sales, equivalent to $7.42M. Other significant revenue streams include General Wellness and Outside the United States. Understanding this composition is critical for investors evaluating how ECOR navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, electroCore, Inc. maintains a gross margin of 88.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -16.06%, while the net margin is -13.82%. These profitability ratios, combined with a Return on Equity (ROE) of 709.52%, provide a clear picture of how effectively ECOR converts its operational activities into shareholder value.

In the context of the broader market, ECOR competes directly with industry leaders such as CRDF and SKIN. With a market capitalization of $81.22M, it holds a leading position in the sector. When comparing efficiency, ECOR's gross margin of 88.47% stands against CRDF's 100.00% and SKIN's 68.42%. Such benchmarking helps identify whether electroCore, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 86.53% in Q2 2026, which is strong, but it continues to report net losses, including a net income of -3,059,000 USD in Q2 2026. Revenue has been increasing, reaching 9,484,000 USD in Q2 2026, but the overall financial health remains concerning due to ongoing losses.